[THE INVESTOR] On Oct. 12, Pharma Research Products (214450) rose 0.22% to 45,500 won (US$40.49). It had declined 11.37% through the past month. Standard deviation, which indicates variableness, records 1.9% on the same period of time over one month.

Compared with its close competitors within the same industry, KOSDAQ, the monthly volatility of Pharma Research Products as at a low level, the earnings rate over one month was also the lowest with decline of stock price. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was -5.9%. By tumbling of stock price, the return-on-risk is the lowest among its peer group in spite of low volatility. Moreover, compared with the KOSDAQ industry, the return-on-risk is below the industrial mean, -0.7, and thus the industrial comparison performance was not so good.

From Oct. 4, foreigners have been continuously buying Pharma Research Productsduring the past 6 trading days. As a shareholding sum by investor group for the past 4 weeks, foreigners have sold 2,239 shares with maintenance of a selling position and institutions have sold 714 shares with dominant selling. However, during the same period, individuals have bought 2,953 shares with an increasing position.

Cumulated shareholdings per investor group (1Mo) Total shareholdings per investor group

By HeRo (hero@heraldcorp.com)

This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.